IMI 2 - Call 2 2014 - Ebola and other filoviral haemorrhagic fevers
© AryanRaj - stock.adobe.com
An ambitious IMI programme to accelerate the development of vaccines and treatments against Ebola and other filoviral haemorrhagic fevers is currently under preparation. A fast-track call for proposals is likely to be launched in the near future. More information will be published shortly on the IMI website.
According to the World Health Organization’s latest reports, over 10 000 people have contracted Ebola virus disease (EVD) in the current outbreak, and around 5 000 have died. The vast majority of cases are in just three west African countries: Guinea, Liberia and Sierra Leone. There are currently no approved treatments or vaccines for Ebola, although a number of treatments and vaccines are now being tested.
Call topics
- Topic 1: Vaccine development Phase I, II, and III
- Topic 2: Manufacturing capability
- Topic 3: Stability of vaccines during transport and storage
- Topic 4: Deployment and compliance of vaccination regimens
- Topic 5: Rapid diagnostic tests
Full Proposals must be submitted via the IMI electronic submission tool SOFIA (Submission OF Information Application). No other means of submission will be accepted.
To access SOFIA, Applicant Consortium Coordinators will need to complete a Request for Access to the tool.
SOFIA will be opened for submission of proposals on 22 November 2014 and will close at the submission deadline on 1 December at 17:00 CET. The proposal may be updated online prior to the submission deadline. Please note that the submit button must be pressed to submit the proposal for evaluation.
